Clinical Outcomes Data
The measurement program behind MindScape Retreat's Anxiety & General Wellness Protocol: validated instruments from baseline through scheduled follow-up.
The live analytics dashboard below draws directly from MindScape Retreat's clinical records system for the Anxiety and General Wellness Protocol, which treats four clinically distinct presentations: generalized anxiety disorder (GAD), comorbid anxiety-depression, SSRI discontinuation syndrome, and general wellness optimization. It renders cohort data only once enough guests have completed paired assessments. This multi-population design reflects ibogaine's transdiagnostic mechanism: the same neurobiological actions that recalibrate the amygdala and quiet default mode network hyperactivity in GAD also drive symptom resolution in comorbid presentations and serotonergic renormalization in SSRI discontinuation syndrome. Three validated instruments serve as the primary measurement framework: the GAD-7 for anxiety severity, the PHQ-9 for depressive comorbidity, and the WEMWBS (Warwick-Edinburgh Mental Wellbeing Scale) for positive psychological functioning.
The inclusion of the WEMWBS alongside symptom-reduction instruments is clinically significant. Most psychiatric outcome research focuses exclusively on the reduction of pathological symptoms, measuring the absence of suffering rather than the presence of wellbeing. The WEMWBS, validated across large population samples and increasingly adopted in psychedelic medicine research, captures positive psychological dimensions including optimism, meaningful engagement, close relationships, and emotional flexibility that the GAD-7 and PHQ-9 are not designed to detect. The dashboard tracks improvement across all three instruments to provide a complete picture of clinical change.
Guests across all four presentations consistently describe a response pattern that supports a unified neurobiological explanation for ibogaine's anxiolytic effects. Anxiety reduction as measured by the GAD-7 follows a rapid-onset pattern, with the steepest decline occurring within the first 72 hours post-treatment, a timeline consistent with ibogaine's documented 5-HT2A serotonergic agonism and sigma-1 receptor activity, both of which modulate amygdala reactivity and threat-processing thresholds on a pharmacological timescale. This rapidity of onset distinguishes ibogaine from SSRIs, which require weeks to produce measurable GAD-7 changes through slower synaptic remodeling pathways.
The WEMWBS trajectory is particularly instructive because it moves in the positive direction, higher scores represent better outcomes, and its improvement parallels the GAD-7 reduction rather than lagging behind it. This simultaneity suggests that ibogaine is not merely relieving pathological symptoms through suppression, but generating genuine positive neurobiological change through BDNF and GDNF upregulation, neuroplasticity enhancement, and the expanded emotional range that follows default mode network quieting. The convergence of symptom reduction on the GAD-7 and wellbeing gain on the WEMWBS within the same treatment window is not typical of pharmacological or psychotherapeutic interventions studied in anxiety disorder research.
Study Overview
Four Presentations. A Unified Neurobiological Framework.
Our Anxiety and General Wellness Protocol treats four distinct but neurobiologically related presentations: primary generalized anxiety disorder (GAD), comorbid anxiety and depression, SSRI discontinuation syndrome, and general wellness optimization or resilience enhancement without a primary psychiatric diagnosis.
The multi-presentation design reflects a clinical hypothesis that ibogaine's neurobiological mechanism (amygdala recalibration, default mode network modulation, and serotonergic rebalancing) addresses a common pathway underlying anxiety in its clinical, comorbid, iatrogenic, and subclinical expressions. Most guests arrive having tried at least one prior treatment approach, including SSRIs, benzodiazepines, cognitive-behavioral therapy, or a combination thereof, with inadequate response.
Primary outcome measures included the Generalized Anxiety Disorder 7-item scale (GAD-7), the Patient Health Questionnaire-9 (PHQ-9) for depressive comorbidity, the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), and a Visual Analog Scale for Wellbeing (Wellbeing VAS). Sleep quality is assessed alongside. Outcomes are tracked on a fixed schedule from baseline through 90-day follow-up, and cohort aggregates publish at /outcomes once at least 20 people have paired data.
The GAD-7 and PHQ-9 are the two primary symptom-reduction instruments in this program. The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a widely validated, 7-item self-report instrument scored from 0 to 21, with clinical thresholds at 5 (mild anxiety), 10 (moderate anxiety), and 15 (severe anxiety). It serves both as a diagnostic screening tool and as a continuous outcome measure sensitive to treatment-related change. The PHQ-9 (Patient Health Questionnaire-9) assesses depressive severity across nine DSM-5 criteria, scored from 0 to 27, with thresholds at 5 (mild), 10 (moderate), 15 (moderately severe), and 20 (severe depression). In this program, the PHQ-9 captures depressive comorbidity and monitors for any depression emergence in the GAD-primary and wellness groups.
Guests in this program typically arrive in the moderate-to-severe anxiety range, consistent with a population whose symptoms have been insufficiently controlled by prior SSRI, benzodiazepine, or psychotherapy interventions, and often with depressive scores straddling the moderate threshold. The clinical reality is that anxiety and depression in this population are rarely isolated: they co-emerge from shared neurobiological substrates that ibogaine's multi-receptor mechanism addresses simultaneously.
The symptom-reduction picture captured by the GAD-7 and PHQ-9 is necessary but not sufficient to characterize the clinical change guests describe. A significant portion of what patients describe, and what motivates them to seek treatment in the first place, is the erosion of positive psychological function: the loss of ease, spontaneity, social engagement, and a felt sense of safety in the world. We measure these dimensions directly through the WEMWBS, sleep quality, and the Wellbeing VAS, instruments designed to detect the presence of psychological health rather than merely the absence of diagnosed symptoms. Because the WEMWBS and Wellbeing VAS are positive-direction scales, higher scores indicate better outcomes, a distinction that matters when reading any wellbeing data.
Published psychedelic research and the pattern guests consistently describe converge on the transdiagnostic mechanism hypothesis: ibogaine does not simply suppress anxiety through one pathway while leaving other dimensions of psychological function unchanged. Instead, it produces a multi-axis neurobiological reorientation (serotonergic rebalancing, amygdala recalibration, default mode network quieting, and BDNF-mediated neuroplasticity) that simultaneously addresses the neurological substrates of anxiety, depression, and impaired wellbeing. Guests with comorbid anxiety and depression consistently describe both dimensions improving together, which challenges the conventional pharmacological model of treating anxiety and depression as sequentially addressable conditions requiring separate or additive interventions.
Guests frequently describe states of psychological openness, gratitude, and relational connection during the treatment experience that consolidate into durable wellbeing improvements through the post-treatment neuroplasticity window. How we measure this, and when cohort aggregates will publish, is presented in the methodology section below.
Study Design & Methodology
A measured clinical program across four anxiety-spectrum presentations with standardized instruments, rigorous safety monitoring, and 90-day longitudinal follow-up.
Prospective, single-center measurement program enrolling four presentations: primary GAD, comorbid anxiety-depression, SSRI discontinuation syndrome, and general wellness optimization. Written informed consent. 90-day longitudinal follow-up. Cohort aggregates publish at mindscaperetreat.com/outcomes once a presentation reaches at least 20 people with paired assessments.
Adults aged 18 to 60. GAD group: GAD-7 ≥ 10 (moderate anxiety). Comorbid group: GAD-7 ≥ 10 and PHQ-9 ≥ 10. SSRI discontinuation: documented SSRI/SNRI discontinuation syndrome persisting > 3 months post-cessation. Wellness: subjective wellbeing complaint without clinical diagnosis. All groups: cardiac clearance (QTc < 450ms), completion of any required medication taper.
Primary: GAD-7 (0 to 21) for anxiety severity, PHQ-9 (0 to 27) for depressive comorbidity. Secondary: Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS, 14 to 70, higher = better), VAS Wellbeing (0 to 100, higher = better), VAS Sleep Quality (0 to 10, higher = better). All instruments validated for mental health outcome assessment with published normative data.
Baseline (pre-treatment), 72h post-ibogaine, Day 7, Day 14 (discharge), Day 30, Day 60, Day 90 follow-up. SSRI discontinuation sub-group: additional daily symptom diary during first 14 days to capture discontinuation syndrome resolution trajectory.
MindScape's current standard of care performs SSRI, SNRI, benzodiazepine, and Z-drug tapers onsite under continuous physician supervision and telemetry, with twice-daily ibogaine TA (total alkaloid) booster doses bridging serotonergic and GABAergic tone during washout. Patients arrive on their current prescribed dose; the HCl flood dose is administered only after titration to a protocol-defined safe threshold. Before the onsite TA-bridging protocol was finalized, guests completed pre-arrival APA-guideline SSRI tapers and pre-arrival Ashton-protocol benzodiazepine tapers. No guest receives ibogaine with active SSRI/SNRI exposure. Pre-arrival contraindications that remain non-negotiable across all eras of practice: MAOIs, tricyclic antidepressants, lithium, tramadol, methadone, long-acting opioids, and Class III antiarrhythmics.
Continuous cardiac telemetry during treatment. Serotonin syndrome monitoring per Hunter criteria for 48h post-ibogaine. PHQ-9 item 9 (suicidality screening) administered at every assessment timepoint. Psychiatric safety protocol with crisis intervention pathway for any patient reporting worsening suicidal ideation.
Mechanism of Action
Amygdala Recalibration, Default Mode Network Quieting, and Serotonergic Rebalancing.
Generalized anxiety disorder is neurobiologically rooted in amygdala hyperreactivity and disrupted prefrontal cortical regulation of threat appraisal. The anxious brain is caught in a persistent state of threat anticipation driven by an amygdala that responds to ambiguity and uncertainty as though they were confirmed dangers. Conventional pharmacological approaches, primarily SSRIs and benzodiazepines, manage this dysregulation chemically without recalibrating the underlying circuit.
Ibogaine produces a distinct and documented recalibration of amygdala reactivity through its combined action on serotonin, sigma-1, and NMDA receptor systems. The 5-HT2A agonist activity initiates a window of reduced fear generalization and enhanced emotional flexibility during which the amygdala's chronic threat threshold can reset toward a more accurate, less reactive baseline. This is the same mechanism that drives the anti-anxiety effects observed with psilocybin in clinical research, but ibogaine's broader receptor profile adds sigma-1 neuroprotection and NMDA-mediated cognitive flexibility that psilocybin does not provide.
The default mode network (DMN), the brain's self-referential processing system, is chronically overactive in generalized anxiety, generating the future-oriented worry loops and rumination that define the clinical experience of GAD. Ibogaine's temporary quieting of DMN hyperactivity creates a window of reduced self-referential processing that allows anxiety patterns to be interrupted and reconsolidated. Combined with the serotonergic rebalancing that addresses the chronic low-grade serotonin deficit documented in anxiety disorder, the result is a comprehensive neurobiological reorientation that conventional treatments approach only partially.
Sub-Population Analysis
GAD, Comorbid Anxiety-Depression, SSRI Discontinuation & Wellness: What We See Clinically
Guests with primary GAD consistently describe the clearest shift on anxiety-specific measures. Qualitative reports across this group describe a subjective shift from pervasive anticipatory dread to a baseline sense of calm that patients described as previously unrecognizable. Many characterized the shift not as the absence of anxiety but as the return of a capacity for genuine ease they had not experienced in years.
Guests with comorbid anxiety and depression describe improvement across both dimensions together. This dual-axis improvement reflects ibogaine's simultaneous action on the serotonergic and neuroplastic pathways implicated in both conditions. Patients in this group who had failed combined SSRI/therapy regimens for both conditions showed the most pronounced improvements, consistent with ibogaine's documented efficacy in treatment-resistant presentations.
Guests arriving with SSRI discontinuation syndrome present unique clinical complexity. Patients experiencing post-SSRI discontinuation syndrome (characterized by brain zaps, somatic anxiety, depersonalization, derealization, emotional blunting, and protracted withdrawal) have often struggled with symptom resolution for a year or more. Ibogaine's serotonergic recalibration is consistently described as bringing relief within days of treatment. General wellness guests describe meaningful improvements in WEMWBS and Wellbeing VAS scores despite not meeting diagnostic thresholds at baseline, reflecting ibogaine's capacity for wellness optimization beyond clinical symptom reduction.
Key Clinical Findings
Six findings, from published research and consistent clinical observation, that define ibogaine's profile across anxiety-spectrum presentations.
Every guest in the anxiety program is measured on the GAD-7 from baseline through 90-day follow-up, and cohort aggregates publish at /outcomes once at least 20 people have paired data. We publish measured group results, never invented figures.
In Stanford Medicine's published veteran study, anxiety improved sharply alongside PTSD and depression within a month of ibogaine treatment, the strongest peer-reviewed signal that a single session can move anxiety from the clinical range toward subclinical levels.
Guests with comorbid anxiety and depression consistently describe both dimensions improving together. Simultaneous movement on both axes from a single intervention challenges the conventional paradigm of sequential or combinatorial pharmacotherapy for comorbid anxiety-depression.
Guests with protracted SSRI discontinuation syndrome (brain zaps, depersonalization, somatic anxiety) consistently describe rapid resolution in the first week after treatment. There is no FDA-approved treatment for protracted SSRI discontinuation, which is why we measure this presentation so closely from baseline through follow-up.
The WEMWBS (14 to 70) distinguishes low wellbeing (below 32) from high wellbeing (above 50). Guests who arrive for wellness optimization rather than a clinical diagnosis often describe some of the fastest subjective shifts, suggesting ibogaine's neuroplasticity-enhancing mechanism benefits subclinical as well as clinical presentations.
Sleep quality is tracked on a 0 to 10 scale across every presentation. Qualitative reports consistently describe sleep normalization as the earliest observable treatment effect, often preceding anxiolytic and mood effects by a day or two, consistent with ibogaine's documented serotonergic rebalancing of sleep architecture.
Clinical Protocol
10-Day Anxiety & Wellness Protocol
Psychiatric Evaluation & Sub-Population Classification
All anxiety and wellness candidates receive a full psychiatric assessment including GAD-7 and PHQ-9 scoring, WEMWBS baseline, medication history, prior treatment timeline, and a structured clinical interview exploring the phenomenology of their anxiety. Candidates are classified into the most appropriate sub-population protocol (GAD-primary, comorbid, SSRI discontinuation, or wellness) to ensure protocol alignment. SSRI discontinuation candidates receive additional assessment of discontinuation symptom severity and timeline.
Medical Screening & Medication Taper Planning
Full bloodwork, 12-lead EKG, cardiac clearance, and a thorough medication interaction review are completed prior to acceptance. Patients currently on SSRIs, SNRIs, or benzodiazepines require a supervised taper protocol prior to ibogaine administration. SSRI and SNRI tapering is clinically managed to avoid exacerbating discontinuation symptoms while ensuring safe ibogaine administration. Benzodiazepine tapers follow established protocols with cardiovascular and neurological monitoring.
Individualized Ibogaine Protocol Design
Our medical director designs a personalized ibogaine dosing protocol tailored to the patient's sub-population profile, symptom severity, medication history, and wellness goals. Anxiety-primary protocols emphasize amygdala recalibration and serotonergic rebalancing. SSRI discontinuation protocols incorporate specific alkaloid ratios designed to support serotonergic renormalization. Wellness protocols are calibrated for neuroplasticity enhancement without excess intensity for patients without significant baseline pathology.
Treatment at MindScape Retreat, Cozumel
Ibogaine is administered in our medically-equipped sanctuary on Cozumel Island under continuous physician and nursing supervision. The therapeutic environment (jungle quiet, natural light, dedicated care staff, and an intimate retreat setting) is specifically selected to minimize ambient stress and support the emotional openness that anxiety patients in particular require for deep therapeutic processing. Cardiac monitoring is maintained throughout the treatment session and immediate recovery period.
Integration Therapy, Wellbeing Practices & Aftercare
Each patient departs with a sub-population-specific integration plan. GAD integration focuses on cognitive restructuring of worry patterns and somatic regulation practices during the enhanced neuroplasticity window. Comorbid integration addresses both anxiety and depressive behavioral patterns simultaneously. SSRI discontinuation integration includes structured nervous system regulation practices and symptom monitoring. Wellness integration focuses on consolidating the expanded wellbeing capacity generated by treatment. All patients receive scheduled clinical check-ins at 30, 60, and 90 days.
Frequently Asked Questions
Questions About Ibogaine for Anxiety & General Wellness
Peer-Reviewed References
Clinical interpretations draw on the following published research in psychedelic medicine, neuroplasticity, and anxiety-spectrum disorders.
- Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
- Carhart-Harris RL, Friston KJ. The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas. Brain. 2010;133(4):1265-1283. doi:10.1093/brain/awq010
- Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019;45(2):161-169.
- Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.
- He DY, McGough NN, Ravindranathan A, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619-628.
- Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addict Behav. 2019;97:111-121. doi:10.1016/j.addbeh.2018.08.027
- Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving. Clin Psychol Rev. 2009;29(6):519-534.
- Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression. Lancet Psychiatry. 2016;3(7):619-627.
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.